Detoxifying chemotherapy with genetics-guided stem cell modeling: A personalized affair

Area of Science:

• Genetics
• Cardiology
• Pharmacogenomics

Background:

• Doxorubicin chemotherapy can cause heart damage (cardiotoxicity) in some patients, while others are unaffected.
• The genetic basis for this differential response remains largely unknown.

Purpose of the Study:

• To identify genetic factors contributing to doxorubicin cardiotoxicity.
• To explore potential therapeutic targets for preventing chemotherapy-induced heart damage.

Main Methods:

• Utilized genome-edited induced pluripotent stem cells (iPSCs) from patients.
• Investigated the role of specific genetic variants in cellular models of cardiotoxicity.

Main Results:

• Identified a common coding variant in the retinoic acid receptor gamma (RARG) gene as a causal risk factor for doxorubicin cardiotoxicity.
• Demonstrated that this RARG variant significantly increases susceptibility to chemotherapy-induced heart damage.

Conclusions:

• A specific RARG genetic variant is a significant predictor of doxorubicin cardiotoxicity.
• Targeting RARG offers a promising pharmacogenomic strategy to protect patients from cardiotoxicity during chemotherapy.